Gillid: readcivir production has accelerated clinical data is expected to be released in the near future

category:Hot
 Gillid: readcivir production has accelerated clinical data is expected to be released in the near future


It is expected that the leading clinical trial research unit will release more details in the near future

Radcivir is a broad-spectrum antiviral drug under development, which has not been approved in any country in the world. In vitro and in vivo animal models, radcivir demonstrated its activity against mers and SARS virus pathogens. They are also coronaviruses, similar in structure to 2019-ncov. Limited preclinical data for mers and SARS suggest that radcivir may have potential activity for 2019 ncov.

At present, Gilead has reached an agreement with the Chinese health sector to support two clinical trials for 2019-ncov infected people to determine the safety and effectiveness of ridcivir as a potential treatment for coronavirus. One of the studies evaluated the efficacy of ridcivir in the treatment of patients with 2019 ncov infection who were hospitalized but did not show significant clinical symptoms (such as the need for additional oxygen inhalation), while the other evaluated the efficacy of ridcivir in the treatment of patients with more severe clinical symptoms (such as the need for oxygen inhalation).

The two clinical trials, led by Chinese researchers, were conducted in Wuhan. Gilead said it would provide the drugs needed for the study free of charge and provide support for the design and implementation of the study. It is expected that the leading research unit of the clinical trial will release more details in the near future.

We are speeding up production and it is too early to discuss compulsory licensing

The patent of ridacivir has also aroused controversy recently. Wuhan Virus Research Institute issued a statement on February 4, saying: for ridacivir, a drug that has not yet been listed in China and has intellectual property barriers, we issued it according to international practice from the perspective of protecting national interests, and applied for a Chinese invention patent (the use of anti 2019 new coronavirus) on January 21, and will Access to major countries in the world through PCT (patent cooperation agreement). If relevant foreign enterprises intend to contribute to Chinas epidemic prevention and control, we agree that we will not require the implementation of the rights claimed in the patent for the time being if the country needs it.

As soon as the statement was issued, it triggered a discussion about the patent of Ridgeway. Geely said it has developed readciway and has patents in the United States, China and the rest of the world. In 2016, Geely applied for more patents in China and around the world for radcivirs application in coronavirus. In China, patent applications for coronavirus applications have yet to be approved.

Gillid said he had no right to interfere with whether the Patent Office granted patents to Chinese researchers. The patent application of Wuhan Virus Research Institute was submitted more than three years after Gilead filed the application. The consideration of the application will integrate the current known knowledge of the synthetic drug and the patent under application. The company cannot comment on the details of the patent application of the researchers, because the content of the patent application will be published 18 months later.

Geely also said that it was too early to discuss any compulsory license or other types of license at this stage, and the company did not have any discussions with regulators on the production and supply costs or financial returns of Geely.

(function() {(window. Slotbydup = window. Slotbydup| []). Push ({ID: u5811557, container: ssp_, async: true});}) (); as a drug under research, radcivir has not been approved in any country in the world. Previously, in response to the outbreak of Ebola in West Africa in recent years, Gilead expanded the production of radcivir, established product inventory to cope with the future pandemic, and increased the inventory of raw materials for manufacturing radcivir. Gilead said it was using this inventory to meet the needs of compassionate drugs and two clinical trials currently planned to be conducted in China. Drug supply has always been the focus of the industry. Although it has not been determined whether the drug can safely and effectively treat 2019 ncov infection, considering the urgency of the current situation, Gilead is taking a variety of measures to speed up the production progress and increase the supply, including accelerating the purchase of raw materials, the production of APIs and drugs. Extended reading: about 80 doctors and patients with pneumonia in the hospital of Wuhan mental health center, a family of 6 and 5 passengers in Zhuhai who were confirmed to have pneumonia on the bus were also infected with real-time updated map of new pneumonia epidemic situation. Source: new Beijing Daily Author: Zhang Xiulan editor in charge: Lin Qihui ufe64 nb13068

As a drug under research, radcivir has not been approved in any country in the world. Previously, in response to the outbreak of Ebola in West Africa in recent years, Gilead expanded the production of radcivir, established product inventory to cope with the future pandemic, and increased the inventory of raw materials for manufacturing radcivir. Gilead said it was using this inventory to meet the needs of compassionate drugs and two clinical trials currently planned to be conducted in China.

Drug supply has always been the focus of the industry. Although it has not been determined whether the drug can safely and effectively treat 2019 ncov infection, considering the urgency of the current situation, Gilead is taking a variety of measures to speed up the production progress and increase the supply, including accelerating the purchase of raw materials, the production of APIs and drugs.